The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy
- PMID: 20832018
- DOI: 10.1016/j.semradonc.2010.05.007
The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy
Abstract
Both the p53- and E2F1-signaling pathways are defective in almost all types of tumors, suggesting very important roles for their signaling networks in regulating the process of tumorigenesis and therapy response. Studies on Radiation Therapy Oncology Group tissue samples have identified aberrant expression of p53, MDM2 (an E3 ubiquitin ligase that targets p53 for proteosomal degradation), and p16 (an upstream regulator of retinoblastoma and hence E2F1 in prostate cancer); abnormal expression of these biomarkers has been associated with clinical outcome after radiotherapy ± androgen deprivation therapy. Although the proapoptotic properties of p53 are well documented, a relatively new aspect of p53 function as an active mediator of prosurvival signaling pathways is now emerging. E2F1 is a transcription factor that possesses both proapoptotic and prosurvival properties. Thus, the role of E2F1 in the process of tumorigenesis versus apoptosis is a contested issue that needs to be resolved. Furthermore, the role of E2F1 in DNA repair is being increasingly recognized. Thus, novel approaches to curb the prosurvival and DNA repair capability of E2F1 while promoting apoptotic function are of interest. In this review, we discuss the challenges involved in targeting the p53/E2F1 pathways and the crosstalk networks, and further propose potential therapeutic strategies for prostate cancer management.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Antisense MDM2 enhances E2F1-induced apoptosis and the combination sensitizes androgen-sensitive [corrected] and androgen-insensitive [corrected] prostate cancer cells to radiation.Mol Cancer Res. 2008 Nov;6(11):1742-54. doi: 10.1158/1541-7786.MCR-08-0102. Mol Cancer Res. 2008. PMID: 19010821 Free PMC article.
-
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.Oncogene. 2007 May 24;26(24):3473-81. doi: 10.1038/sj.onc.1210136. Epub 2006 Dec 4. Oncogene. 2007. PMID: 17146434
-
Heavy ion radiation-induced DNA damage mediates apoptosis via the Rpl27a-Rpl5-MDM2-p53/E2F1 signaling pathway in mouse spermatogonia.Ecotoxicol Environ Saf. 2020 Sep 15;201:110831. doi: 10.1016/j.ecoenv.2020.110831. Epub 2020 Jun 11. Ecotoxicol Environ Saf. 2020. PMID: 32535367
-
E2F1 apoptosis counterattacked: evil strikes back.Trends Mol Med. 2013 Feb;19(2):89-98. doi: 10.1016/j.molmed.2012.10.009. Epub 2012 Dec 5. Trends Mol Med. 2013. PMID: 23219173 Review.
-
Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance.Drug Resist Updat. 2010 Aug-Oct;13(4-5):119-31. doi: 10.1016/j.drup.2010.06.001. Epub 2010 Aug 1. Drug Resist Updat. 2010. PMID: 20675184 Review.
Cited by
-
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy.Int J Cancer. 2014 Nov 1;135(9):2085-95. doi: 10.1002/ijc.28862. Epub 2014 Apr 5. Int J Cancer. 2014. PMID: 24658971 Free PMC article.
-
Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3. Cancer Biol Ther. 2013. PMID: 23792570 Free PMC article.
-
Molecular pathogenesis and progression of prostate cancer.Semin Oncol. 2013 Jun;40(3):244-58. doi: 10.1053/j.seminoncol.2013.04.001. Semin Oncol. 2013. PMID: 23806491 Free PMC article. Review.
-
Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator.PLoS One. 2013 Oct 11;8(10):e77643. doi: 10.1371/journal.pone.0077643. eCollection 2013. PLoS One. 2013. PMID: 24147044 Free PMC article.
-
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.Nat Rev Urol. 2011 Aug 2;8(10):562-8. doi: 10.1038/nrurol.2011.107. Nat Rev Urol. 2011. PMID: 21811228 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous